(Editor's Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
iCo Therapeutics (ICO.V) (OTCQX:ICOTF) is a small cap Canadian biotechnology company focused on the development of novel therapeutics for the treatment of ophthalmologic and infectious diseases. The company's lead development candidate is iCo-007, a second generation antisense drug for the treatment of diabetic macular edema. The completion of enrollment for the 208 patient iDEAL trial was announced in June 2013, and top-line results are expected in the first quarter of 2014.
Our interest in iCo Therapeutics follows in part from our previous survey, which found a high level of Phase II clinical success associated with locally administered antisense...
Only subscribers can access this article, which is part of the PRO research library covering 3,758 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: